1
|
Liaw YW, Lin CY, Lai YS, Yang TC, Wang CJ, Whang-Peng J, Liu LF, Lin CP, Nieh S, Lu SC, Hwang J. A vaccine targeted at CETP alleviates high fat and high cholesterol diet-induced atherosclerosis and non-alcoholic steatohepatitis in rabbit. PLoS One 2014; 9:e111529. [PMID: 25486007 PMCID: PMC4259298 DOI: 10.1371/journal.pone.0111529] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/04/2014] [Accepted: 09/28/2014] [Indexed: 01/22/2023] Open
Abstract
Low HDL-C levels are associated with atherosclerosis and non-alcoholic steatohepatitis, and increased levels may reduce the risk of these diseases. Inhibition of cholesteryl ester transfer protein (CETP) activity is considered a promising strategy for increasing HDL-C levels. Since CETP is a self-antigen with low immunogenicity, we developed a novel CETP vaccine (Fc-CETP6) to overcome the low immunogenicity of CETP and for long-term inhibition of CETP activity. The vaccine consists of a rabbit IgG Fc domain for antigen delivery to antigen-presenting cells fused to a linear array of 6 repeats of a CETP epitope to efficiently activate B cells. Rabbits were fed a high fat/cholesterol (HFC) diet to induce atherosclerosis and NASH, and immunized with Fc-CETP6 vaccine. The Fc-CETP6 vaccine successfully elicited anti-CETP antibodies and lowered plasma CETP activity. The levels of plasma HDL-C and ApoA-I were higher, and plasma ox-LDL lower, in the Fc-CETP6-immunized rabbits as compared to the unimmunized HFC diet-fed rabbits. Pathological analyses revealed less lipid accumulation and inflammation in the aorta and liver of the Fc-CETP6-immunized rabbits. These results show that the Fc-CETP6 vaccine efficiently elicited antibodies against CETP and reduced susceptibility to both atherosclerosis and steatohepatitis induced by the HFC diet. Our findings suggest that the Fc-CETP6 vaccine may improve atherosclerosis and NASH and has high potential for clinical use.
Collapse
Affiliation(s)
- Yi-Wei Liaw
- Institute of Biochemistry and Molecular Biology, National Yang-Ming University, Taipei, Taiwan
- Department of Biochemistry, Medical College, Taipei Medical University, Taipei, Taiwan
| | - Chi-Yu Lin
- Graduate Institute of Life Sciences, National Defense Medical Center, Taipei, Taiwan
- Department of Biochemistry, Medical College, Taipei Medical University, Taipei, Taiwan
| | - Yu-Sheng Lai
- Department of Biochemistry and Molecular Biology, College of Medicine, National Taiwan University, Taipei, Taiwan
| | - Tzu-Chung Yang
- Department of Biochemistry and Molecular Biology, College of Medicine, National Taiwan University, Taipei, Taiwan
| | - Chau-Jong Wang
- Institute of Biochemistry and Biotechnology, Chung Shan Medical University, Taichung, Taiwan
| | - Jacqueline Whang-Peng
- Institute of Cancer Biology and Drug Discovery, Taipei Medical University, Taipei, Taiwan
| | - Leroy F. Liu
- Institute of Cancer Biology and Drug Discovery, Taipei Medical University, Taipei, Taiwan
- Department of Pharmacology, The University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, Piscataway, New Jersey, United States of America
| | - Chia-Po Lin
- Division of Drug Biology, Bureau of Food and Drug Analysis, Department of Health, Executive Yuan, Taiwan
| | - Shin Nieh
- Department of Pathology, National Defense Medical Center and Tri-Service General Hospital, Taipei, Taiwan
| | - Shao-Chun Lu
- Department of Biochemistry and Molecular Biology, College of Medicine, National Taiwan University, Taipei, Taiwan
- * E-mail: (JH); (SCL)
| | - Jaulang Hwang
- Institute of Biochemistry and Molecular Biology, National Yang-Ming University, Taipei, Taiwan
- Department of Biochemistry, Medical College, Taipei Medical University, Taipei, Taiwan
- * E-mail: (JH); (SCL)
| |
Collapse
|
2
|
Chiang HL, Lin CY, Jan FD, Lin YS, Hsu CT, Whang-Peng J, Liu LF, Nieh S, Lin CC, Hwang J. A novel synthetic bipartite carrier protein for developing glycotope-based vaccines. Vaccine 2012; 30:7573-81. [PMID: 23099332 PMCID: PMC3513549 DOI: 10.1016/j.vaccine.2012.10.041] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2012] [Revised: 10/06/2012] [Accepted: 10/11/2012] [Indexed: 11/18/2022]
Abstract
Development of successful vaccines against glycotopes remains a major challenge. In the current studies, we have successfully developed a novel carrier protein for glycotopes based on the concept of antigen clustering and specific stimulation of T helper cells to mount strong antibody response to glycotopes. The bipartite carrier protein consists of a tandem repeat of a cysteine-rich peptide for docking of clustered glycotopes to effectively activate B cells and an Fc domain for antigen delivery to antigen presenting cells (APCs). To demonstrate its utility, we conjugated the tumor-specific monosaccharide antigen Tn to this novel carrier protein and successfully developed a Tn vaccine against cancer in animal models. The Tn vaccine effectively elicited high-titer IgG1 antibodies against Tn in immunized mice, and effectively suppressed the development of prostate cancer in Transgenic Adenocarcinoma of the Mouse Prostate (TRAMP) mice. Our results suggest that this novel bipartite carrier protein could be effectively used for developing anti-glycotope vaccines such as the anticancer Tn vaccine.
Collapse
Affiliation(s)
- Hsiao-Ling Chiang
- Graduate Institute of Life Sciences, National Defense Medical Center, Taipei, Taiwan
- Institute of Molecular Biology, Academia Sinica, Taipei, Taiwan
- Department of Biochemistry, School of Medicine, Taipei Medical University, Taipei, Taiwan
| | - Chi-Yu Lin
- Graduate Institute of Life Sciences, National Defense Medical Center, Taipei, Taiwan
- Institute of Molecular Biology, Academia Sinica, Taipei, Taiwan
- Department of Biochemistry, School of Medicine, Taipei Medical University, Taipei, Taiwan
| | - Fan-Dan Jan
- Department of Chemistry, National Tsing Hua University, Hsinchu, Taiwan
| | - Yaoh-Shiang Lin
- Department of Otolaryngology-Head and Neck Surgery, National Defense Medical Centre & Tri-Service General Hospital, Taipei, Taiwan
| | - Chia-Tse Hsu
- Institute of Molecular Biology, Academia Sinica, Taipei, Taiwan
| | | | - Leroy F. Liu
- Department of Pharmacology, The University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, Piscataway, NJ 08854, USA
| | - Shin Nieh
- Graduate Institute of Life Sciences, National Defense Medical Center, Taipei, Taiwan
- Department of Pathology, Tri-Service General Hospital, Taipei, Taiwan
| | - Chun-Cheng Lin
- Department of Chemistry, National Tsing Hua University, Hsinchu, Taiwan
| | - Jaulang Hwang
- Graduate Institute of Life Sciences, National Defense Medical Center, Taipei, Taiwan
- Institute of Molecular Biology, Academia Sinica, Taipei, Taiwan
- Department of Biochemistry, School of Medicine, Taipei Medical University, Taipei, Taiwan
| |
Collapse
|